ATE303154T1 - Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv - Google Patents

Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv

Info

Publication number
ATE303154T1
ATE303154T1 AT00971704T AT00971704T ATE303154T1 AT E303154 T1 ATE303154 T1 AT E303154T1 AT 00971704 T AT00971704 T AT 00971704T AT 00971704 T AT00971704 T AT 00971704T AT E303154 T1 ATE303154 T1 AT E303154T1
Authority
AT
Austria
Prior art keywords
trifluridine
hiv
phosphorylase inhibitor
thymidine phosphorylase
treatment
Prior art date
Application number
AT00971704T
Other languages
English (en)
Inventor
Hiroo Hoshino
Kenji Kitazato
Masakazu Fukushima
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE303154T1 publication Critical patent/ATE303154T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT00971704T 1999-11-05 2000-11-01 Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv ATE303154T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31567099A JP4110347B2 (ja) 1999-11-05 1999-11-05 抗ｈｉｖ剤
PCT/JP2000/007676 WO2001034162A1 (fr) 1999-11-05 2000-11-01 Compositions anti-vih

Publications (1)

Publication Number Publication Date
ATE303154T1 true ATE303154T1 (de) 2005-09-15

Family

ID=18068171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00971704T ATE303154T1 (de) 1999-11-05 2000-11-01 Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv

Country Status (6)

Country Link
US (1) US6596720B1 (de)
EP (1) EP1230925B8 (de)
JP (1) JP4110347B2 (de)
AT (1) ATE303154T1 (de)
DE (1) DE60022380T2 (de)
WO (1) WO2001034162A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025575A1 (en) * 2001-09-17 2003-03-27 Board Of Regents, The University Of Texas System Methods and compositions involving thymidine phosphorylase as a marker for hiv infection, aids progression, and drug resistance
EP1539783B1 (de) * 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitoren von nukleosidphosphorylasen und nukleosidasen
JP4852605B2 (ja) 2006-06-30 2012-01-11 大鵬薬品工業株式会社 放射線治療増強剤
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
EP2170053A4 (de) 2007-01-31 2010-06-23 Biosuccess Biotech Company Zusammensetzungen und verfahren für die verwendung von phorbolestern
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
TWI435725B (zh) * 2007-10-11 2014-05-01 Taiho Pharmaceutical Co Ltd The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis
TWI429439B (zh) * 2007-10-11 2014-03-11 Taiho Pharmaceutical Co Ltd And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
WO2013137284A1 (ja) 2012-03-14 2013-09-19 日清ファルマ株式会社 含硫アミノ酸含有組成物
HK1203071A1 (en) 2013-06-17 2015-10-16 大鹏药品工业株式会社 Stabilized crystal of tipiracil hydrochloride, and crystallization method for same
CN103980253B (zh) * 2014-05-06 2015-07-08 济南百诺医药科技开发有限公司 一种5-氯-6-(2-亚氨基吡咯烷基-1-基)甲基-2,4-(1h, 3h)嘧啶二酮盐酸盐的合成方法
CN106317028A (zh) * 2015-11-03 2017-01-11 江苏悦兴药业有限公司 抗肿瘤药物盐酸替比拉西的制备方法及其关键中间体
CN112569250A (zh) * 2020-10-16 2021-03-30 中山大学 三氟尿苷制备hiv-1药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3469533D1 (en) * 1983-05-23 1988-04-07 Taiho Pharmaceutical Co Ltd Novel 2'-deoxy-5-substituted uridine derivatives, processes for preparing the same and antitumor agent containing the same
EP0258412A1 (de) * 1986-02-20 1988-03-09 GREER, Sheldon B. Zubereitung und verfahren zur behandlung von aids und verwandten krankheiten
EP0289229B1 (de) * 1987-04-24 1992-01-29 The Wellcome Foundation Limited Antivirale Mischungen
CA2033448C (en) * 1990-12-31 1996-11-26 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Antiherpes compositions and method of use
CA2033447C (en) * 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
KR100424934B1 (ko) * 1995-03-29 2004-07-27 다이호야쿠힌고교 가부시키가이샤 우라실유도체및이를함유하는항종양효과증강제및항종양제
JP4049477B2 (ja) * 1999-03-23 2008-02-20 大鵬薬品工業株式会社 副作用軽減剤

Also Published As

Publication number Publication date
DE60022380D1 (de) 2005-10-06
EP1230925A4 (de) 2004-06-09
US6596720B1 (en) 2003-07-22
JP4110347B2 (ja) 2008-07-02
EP1230925A1 (de) 2002-08-14
WO2001034162A1 (fr) 2001-05-17
DE60022380T2 (de) 2006-06-08
JP2001131075A (ja) 2001-05-15
EP1230925B1 (de) 2005-08-31
EP1230925B8 (de) 2006-03-01

Similar Documents

Publication Publication Date Title
ATE303154T1 (de) Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
HN1996000017A (es) Isotiazolonas
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
DE60000992D1 (de) Desinfizierende zusammensetzung auf basis von h2o2, säuren und metallionen
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
TR200200068T2 (tr) Nematisital triflüorobütenler
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE69316751D1 (de) Azlaktonfunktionen aufweisende substrate, hornhautprothesen und ihre verwendung
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
BR9902457A (pt) Padrões de adesivo aperfeiçoados para artigos de higiene feminina.
ATE153853T1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DK0768086T3 (da) Behandling af tinnitus med neurobeskyttende virksomme stoffer
EP1319402A4 (de) IgE-ENTSTEHUNGSHEMMSTOFFE
FI945164A7 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
UA37251C2 (uk) Лікарський засіб для лікування або профілактики вірусної інфекції гепатиту в і спосіб лікування вірусної інфекції гепатиту в
ATE275824T1 (de) Antiadhäsive sterole und sterolderivate
WO2003090674A3 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties